Top

Published in:

01-05-2009 | editorial

In search of a better platelet ADP-receptor blocker

Author: F. W. A. Verheugt

Published in: Netherlands Heart Journal | Issue 5/2009

Abstract

The second-generation antiplatelet agents – the inhibitors of the ADP receptor – have proven important in the management of acute coronary syndromes with or without coronary intervention.

CURE Investigators. Effect of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494–502.

Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527–33.

Sabatine M, Cannon CP, Montalescot G, et al. Fibrinolysis with double antiplatelet therapy in ST-elevation acute coronary syndromes. N Engl J Med 2005:352:1179–89.

Chen ZM, Jiang LX, Chen Y, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005;366:1607–21.

Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: the Full Anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation 1998;98:1597–603.

Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading and maintenance dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-Thrombolysis in Myocardial Infarction-44 Trial. Circulation 2007;116:2923–32.

Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–15.

Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine phosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-elevation acute coronary syndromes: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007; 50:1844–51.

Bouman HJ, van Werkum JW, Hackeng CM, Clappers N, ten Berg JM. Cangrelor increases the magnitude of platelet inhibition and reduces interindividual variability in clopidogrel pretreated subjects. Neth Heart J 2009;17:195–8.

Title: In search of a better platelet ADP-receptor blocker
Author: F. W. A. Verheugt
Publication date: 01-05-2009
Publisher: Bohn Stafleu van Loghum
Published in: Netherlands Heart Journal / Issue 5/2009
Print ISSN: 1568-5888
Electronic ISSN: 1876-6250
DOI: https://doi.org/10.1007/BF03086244

Keynote webinar | Spotlight on medication adherence

Springer Medicine

In search of a better platelet ADP-receptor blocker

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2009

Traumatic ascending aortic transection in a patient with a subdural haematoma: timing of surgery

Cangrelor increases the magnitude of platelet inhibition and reduces interindividual variability in clopidogrel-pretreated subjects

Cell therapy for ischaemic heart disease: focus on the role of resident cardiac stem cells

Peer review under review: room for improvement?

Renal failure induces telomere shortening in the rat heart

Isolated left ventricular noncompaction diagnosed by transthoracic threedimensional echocardiography